ABSTRACT. Angiogenesis is essential for tumor progression and is regulated by several angiogenic factors such as vascular endothelial growth factor (VEGF). We investigated the expression and distribution of VEGF and its receptor flt-1 in twelve normal canine tissues in six beagle dogs using immunohistochemistry, RT-PCR and real-time RT-PCR. Immunochemical staining showed that both VEGF and flt-1 were expressed in many tissues and their mRNAs were detected in all organs examined by RT-PCR. Levels of VEGF164 and flt-1 mRNA expression were high in tissues containing many intensely immunopositive cells. The expression levels of VEGF164 and flt-1 mRNA tended to be similar. These results indicated that VEGF and flt-1 are closely associated in canine, as in human tissues, and quantifying their mRNAs might be helpful in evaluating angiogenesis. KEY WORDS: canine, flt-1, VEGF.
Angiogenesis is extremely important for the development and metastasis of solid tumors because tumor-associated vessels can supply oxygen and nutrition to tumor cells for several millimeters. Many factors modulate angiogenesis and they have been investigated as tumor prognostic factors. Among them, vascular endothelial growth factor (VEGF) plays a central role in angiogenesis and mediates vascular permeability by binding to its receptors, flt-1 and flk-1. At least four isoforms of VEGF (VEGF 120, 164, 182, 188) have been identified in the dog and they are produced by alternative splicing during transcription [4] . The predominant form is VEGF164, although each isoform has specific biological activities. Up-regulated VEGF and its receptors in many human solid tumors correlates with a poor prognosis. However, angiogenic factors including VEGF and its receptors in the dog are still poorly understood, although several studies have demonstrated significant correlation among tumor grade and angiogenic factors and/or microvessel density in mammary gland tumors, basal cell tumor, and squamous cell carcinoma in dogs [7, 11] . Furthermore, the expression of the mRNAs for these angiogenic factors in normal canine tissues is not well understood.
Therefore, the present study examines VEGF and flt-1 expression in lung, renal cortex, heart, adrenal, liver, skin, thyroid, intestine, bladder, lymph node, pancreas, and spleen tissues from six healthy beagles using immunohistochemistry, RT-PCR and real-time RT-PCR.
Formalin-fixed, deparaffinized tissue sections were immunohistochemically stained using a streptavidin-biotin immunoperoxidase technique. The primary antibodies were polyclonal rabbit anti-human VEGF (A-20; Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.) and polyclonal rabbit anti-human flt-1 (C-17, Santa Cruz Biotechnology). Negative controls included normal rabbit IgG instead of primary antibody. Immunoreactive intensity was scored as follows: +++ (intense); ++ (moderate); + (weak); -(negative). Over 100 vascular smooth muscle cells in all tissues and over 1,000 lymphocytes in the lymph nodes were counted in each dog and the percentage of positive cells was expressed as means ± S.E.
Total cellular RNA was extracted using the Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA, U.S.A.) according to the manufacturer's instructions. Intestine and bladder specimens were obtained by scratching the luminal surface with glass slides. Extracted RNA was incubated with RNase-free DNase (Promega, Madison, Wis., U.S.A.) before reverse transcription proceeded using the Superscript III first strand synthesis system for RT-PCR (Invitrogen Life Technologies). Oligonucleotide primers against all canine VEGF isoforms and the flt-1 gene were used to amplify specific canine sequences from the generated cDNA (Table 1 ). The PCR reaction with Takara Taq (Takara Shuzo, Ohtsu, Japan) proceeded as follows: denaturation at 94°C for 5 min, 40 cycles of denaturation at 94°C for 30 sec, hybridization at 58°C for 1 min, extension at 72°C for 1 min and final extension at 72°C for 5 min. The PCR products were separated on 2% agarose gels and stained with ethidium bromide.
Real-time PCR proceeded in duplicate on an ABI PRISM 7700 Sequence Analyzer (Applied Biosystems, Foster City, CA, U.S.A.) using the primer sets for VEGF164 and flt-1 and TaqMan Universal PCR Mastermix ® (Applied Biosystems). Expression levels of each mRNA were standardized against 18S ribosomal RNA in corresponding samples and then the amount of expression relative to that in the liver was calculated. Values are expressed as mean ± S.E. Table 2 summarizes the immunohistochemical findings obtained from normal canine tissues using both anti-VEGF and -flt-1 antibodies. In all VEGF-and flt-1-positive cells, the cytoplasm was diffusely stained but bronchiolar epithelial cells showed positive in apical cytoplasm. No heterogeneity of staining properties with both antibodies was observed in the same cell types except for vascular muscle cells and lymphocytes. The staining profiles did not significantly differ according to vessel size or between arteries and veins. Anti-VEGF antibody weakly reacted with 22.4 ± 10.2% of vascular smooth muscle cells, whereas anti-flt-1 antibody reacted with 56.8 ± 24.8% of these in all normal tissues. However, neither antibody reacted with endothelial cells. As to staining properties of inflammatory cells, anti-VEGF antibody stained macrophages and lymphocytes in the lung, lymph nodes, and spleen, whereas anti-flt-1 antibody stained only lymphocytes in the lymph nodes and spleen. Other inflammatory cells including plasma cells were not reacted with both antibodies in this study. Alveolar epithelial cells and bronchiolar smooth muscles were intensely stained and bronchiolar cells were positive that were polarized to the luminal pole with both antibodies (Fig.  1) . In the kidney, glomeruli were negative, whereas proximal, distal and collecting tubules were weakly stained for both antibodies. The myocardium was weakly and diffusely stained with both antibodies. Anti-flt-1 antibody stained the secretory cells of the adrenal cortex and medulla, whereas anti-VEGF antibody stained only cortical cells. In the liver, hepatocytes and the bile duct reacted with both antibodies, whereas Kupffer cells were immunopositive only against anti-VEGF antibody. The epidermis, sebaceous and apocrine glands, as well as erector pili muscles in the skin were positive for both VEGF and flt-1. Anti-VEGF and anti-flt-1 antibody reacted with upper and hair follicles, respectively. No thyroid structures other than vessels were positive for both antibodies. Anti-VEGF antibody weakly stained the goblet cells and muscularis of the intestine, whereas anti-flt-1 antibody was reactive in the muscularis, the nerve plexus, and intensely stained in the microvilli. The transitional epithelium of the bladder reacted with both antibodies and intensely with anti-flt-1 antibody in umbrella cells. In the lymph nodes, anti-flt-1 antibody reacted with 3.9 ± 1.4% of lymphocytes mainly located in T-cell regions, whereas anti-VEGF antibody reacted with 20.9 ± 10.1% of lymphocytes in both T-cell and B-cell regions. No pancreatic structures were VEGF-positive except for the vessels, whereas intercalated ducts and islets weakly reacted with flt-1 antibody. In the spleen, only vascular smooth muscle cells reacted with both antibodies. Bands corresponding to VEGF120, VEGF164, and VEGF182 or VEGF188 appeared after RT-PCR for VEGF in normal canine tissues. The VEGF182 and VEGF188 products migrated as a single band on the gel because the sizes of these cDNAs were similar ( Fig. 2A) . More VEGF164 isoform was expressed than any other isoform. All normal tissues examined expressed flt-1 mRNA (Fig.  2B) . Real-time RT-PCR showed that VEGF164 was the predominant isoform (Fig. 3 ) and the degree of its expression correlated with that of flt-1. Levels of VEGF164 and flt-1 mRNA expression were high in the lung, renal cortex, heart and adrenals, but low in the pancreas, lymph nodes and spleen.
The present study found that VEGF and flt-1 were expressed in all normal canine tissues at the protein and mRNA levels. These results are consistent with findings in human, mouse, rat, and guinea pig tissues [1, 2, 9] . Consistent with the relatively high level of VEGF expression in the lung and heart, the capillaries of these organs are considered to be more permeable than those of many other tissues [1] . The high level of VEGF expression in the renal cortex could be because renal glomeruli have an exceptionally permeable filtration system [1] . The reasons for the negative staining of the renal gromeruli for both VEGF and flt-1 may include that the expression level of VEGF in the glomeruli might be under the limit of detection and major VEGF receptor in the glomeruli is not flt-1 but flk-1 [8] . Our finding that the level of VEGF expression in the spleen was low despite the abundance of vessels indicates that only a few cells express VEGF under normal conditions. Neutralizing VEGF in the lung results in alveolar endothelial cell apoptosis [6] , significant capillary regression in pancreatic islets, thyroid, adrenal cortex, pituitary, choroid plexus, small-intestinal villi, and epididymal adipose tissue [5] . These results indicate that VEGF functions in vascular preservation, a notion supported by our findings. Our results that vascular smooth muscle cells stained with both VEGF and flt-1 antibodies were consistent with those reported by Berse et al. [1] .
Those suggested that VEGF plays a role in maintaining not only the vascular endothelium but also vascular smooth muscle cells by autocrine and paracrine manners. The expression levels of VEGF and flt-1 mRNA among tissues tended to correlate in the present study, indicating that they are closely associated in canine tissues. Although flt-1 has less tyrosine kinase activity than flk-1, some reports have demonstrated that increased flt-1 correlates with that of VEGF and tumor grade [10] . Yonemaru et al. [12] recently reported that VEGF and its receptors might be associated with the malignant proliferation of canine hemangiosarcoma. In addition, flt-1 plays an important role in the pulmonary metastasis of tumors [3] . Therefore tumor characteristics might be better understood by studying flt-1 expression. Our study showed that intensely VEGF or flt-1 immunopositive tissues also expressed high levels of their mRNAs, indicating that quantifying these mRNAs would help to evaluate angiogenesis in canine tissues. Approaches that target VEGF might become a therapeutic strategy against canine tumors, and advances in understanding the role of VEGF in normal physiology will provide insight into the basis of side-effects attributed to the administration of VEGF inhibitors.
